Cargando…

The CINs of Polo-Like Kinase 1 in Cancer

SIMPLE SUMMARY: Many alterations specific to cancer cells have been investigated as targets for targeted therapies. Chromosomal instability is a characteristic of nearly all cancers that can limit response to targeted therapies by ensuring the tumor population is not genetically homogenous. Polo-lik...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cunningham, Chelsea E., MacAuley, Mackenzie J., Vizeacoumar, Frederick S., Abuhussein, Omar, Freywald, Andrew, Vizeacoumar, Franco J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599805/ https://www.ncbi.nlm.nih.gov/pubmed/33066048 http://dx.doi.org/10.3390/cancers12102953

Ejemplares similares

Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia
por: K. Bhanumathy, Kalpana, et al.
Publicado: (2021)

The EphB6 receptor is overexpressed in pediatric T cell acute lymphoblastic leukemia and increases its sensitivity to doxorubicin treatment
por: El Zawily, Amr, et al.
Publicado: (2017)

An integrated computational and experimental study uncovers FUT9 as a metabolic driver of colorectal cancer
por: Auslander, Noam, et al.
Publicado: (2017)

Expression-based analyses indicate a central role for hypoxia in driving tumor plasticity through microenvironment remodeling and chromosomal instability
por: Jing, Anqi, et al.
Publicado: (2018)

Mining the plasma-proteome associated genes in patients with gastro-esophageal cancers for biomarker discovery
por: Vizeacoumar, Frederick S., et al.
Publicado: (2021)

Synthetic lethal interactions of DEAD/H-box helicases as targets for cancer therapy
por: Arna, Ananna Bhadra, et al.
Publicado: (2023)

Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment
por: Paul, James M., et al.
Publicado: (2016)

Enhancing the throughput and multiplexing capabilities of next generation sequencing for efficient implementation of pooled shRNA and CRISPR screens
por: Islam, Md. Fahmid, et al.
Publicado: (2017)

The intrinsically kinase-inactive EPHB6 receptor predisposes cancer cells to DR5-induced apoptosis by promoting mitochondrial fragmentation
por: El Zawily, Amr M., et al.
Publicado: (2016)

APOBEC1 cytosine deaminase activity on single-stranded DNA is suppressed by replication protein A
por: Wong, Lai, et al.
Publicado: (2020)

Molecular characterization of an MLL1 fusion and its role in chromosomal instability
por: Parameswaran, Sreejit, et al.
Publicado: (2018)

A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for N-MYC Overexpressing Neuroendocrine Prostate Cancers
por: Elhasasna, Hussain, et al.
Publicado: (2022)

Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells
por: Miah, Sayem, et al.
Publicado: (2019)

Therapeutic relevance of the protein phosphatase 2A in cancer
por: Cunningham, Chelsea E., et al.
Publicado: (2016)

Identification of novel genes involved in apoptosis of HIV-infected macrophages using unbiased genome-wide screening
por: Dong, Simon X. M., et al.
Publicado: (2021)

Humanized yeast genetic interaction mapping predicts synthetic lethal interactions of FBXW7 in breast cancer
por: Kirzinger, Morgan W. B., et al.
Publicado: (2019)

Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel
por: Plett, Riley, et al.
Publicado: (2022)

EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours
por: Toosi, Behzad M., et al.
Publicado: (2018)

Polo-like kinase 1 as target for cancer therapy
por: Weiß, Lily, et al.
Publicado: (2012)

Putting a bit into the polo-box domain of polo-like kinase 1
por: Park, Jung-Eun, et al.
Publicado: (2015)

Polo-like kinase in trypanosomes: an odd member out of the Polo family
por: Kurasawa, Yasuhiro, et al.
Publicado: (2020)

Molecular characterization of breast cancer cell lines through multiple omic approaches
por: Smith, Shari E., et al.
Publicado: (2017)

The balance of Polo-like kinase 1 in tumorigenesis
por: Lu, Lin-Yu, et al.
Publicado: (2009)

Global phosphoproteomic analysis identifies SRMS-regulated secondary signaling intermediates
por: Goel, Raghuveera Kumar, et al.
Publicado: (2018)

Therapeutic inhibition of polo‐like kinases in anaplastic thyroid cancer
por: Lin, Shu‐Fu, et al.
Publicado: (2021)

Polo-like kinase-1 in DNA damage response
por: Hyun, Sun-Yi, et al.
Publicado: (2014)

Polo-like kinase 1 promotes pulmonary hypertension
por: Chen, Rongrong, et al.
Publicado: (2023)

PhenoM: a database of morphological phenotypes caused by mutation of essential genes in Saccharomyces cerevisiae
por: Jin, Ke, et al.
Publicado: (2012)

Role for polo-like kinase 4 in mediation of cytokinesis
por: Press, Michael F., et al.
Publicado: (2019)

Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1
por: Yun, Sang-Moon, et al.
Publicado: (2009)

A selective inhibitor of the Polo-box domain of Polo-like kinase 1 identified by virtual screening
por: Abdelfatah, Sara, et al.
Publicado: (2018)

Playing POLO-like kinase in NRAS mutant melanoma
por: Chen, Hsin-Yi, et al.
Publicado: (2015)

Polo-Like Kinase 2: From Principle to Practice
por: Zhang, Chuanyong, et al.
Publicado: (2022)

Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers
por: Ward, Alison K., et al.
Publicado: (2016)

Enhanced polo-like kinase 1 expression in myelodysplastic syndromes
por: Min, Kyoung Il, et al.
Publicado: (2019)

Exploring the Binding Nature of Pyrrolidine Pocket-Dependent Interactions in the Polo-Box Domain of Polo-Like Kinase 1
por: Murugan, Ravichandran N., et al.
Publicado: (2013)

Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain
por: Chen, Yunyu, et al.
Publicado: (2016)

FRK inhibits breast cancer cell migration and invasion by suppressing epithelial-mesenchymal transition
por: Ogunbolude, Yetunde, et al.
Publicado: (2017)

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
por: Gjertsen, B T, et al.
Publicado: (2015)

Potential Tumor Suppressor Role of Polo-like Kinase 5 in Cancer
por: Su, Shengqin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g74bin37qg1m02mjeh9ted0u8l